1079843-62-1 Usage
General Description
Hydrazinecarboxylic acid, 2-(2,5-difluorobenzoyl)-, 1,1-diMethylethyl ester is a chemical compound with potential applications in the field of organic synthesis and pharmaceutical research. It is known for its ability to act as a potential building block for the synthesis of various bioactive compounds, such as pharmaceutical drugs. Hydrazinecarboxylic acid, 2-(2,5-difluorobenzoyl)-, 1,1-diMethylethyl ester is often used in the production of drugs and other substances that could have potential therapeutic or medicinal properties. Its precise uses and applications are continually being explored, and it holds promise for further developments in the field of pharmaceutical chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 1079843-62-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,9,8,4 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1079843-62:
(9*1)+(8*0)+(7*7)+(6*9)+(5*8)+(4*4)+(3*3)+(2*6)+(1*2)=191
191 % 10 = 1
So 1079843-62-1 is a valid CAS Registry Number.
1079843-62-1Relevant articles and documents
SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS
-
Page/Page column 315-316, (2010/12/17)
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising thes
SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY
-
Page/Page column 319, (2009/05/28)
The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising t
MITOTIC KINESIN INHIBITORS
-
Page/Page column 28, (2010/10/20)
The present invention relates to oxadiazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
